Remove 2021 Remove Access Remove DEA Remove Policy
article thumbnail

Tell Congress Not To Allow Trump To Roll Back Medical Marijuana Protections

NORML

The latest offense is his recently released 2021 federal budget proposes slashing all legal protection for state medical marijuana programs and potentially jeopardizing the patients that rely on them. No patient should have to worry about losing access to cannabis treatment options. The data speaks for itself.

Marijuana 352
article thumbnail

Is The DEA Poised To Regulate Telepharmacy?

Cannabis Law Report

02 December 2021. On November 16, 2021, the Drug Enforcement Agency (DEA) issued an advance notice of proposed rulemaking , exploring whether or not to create new federal regulations governing the practice of telepharmacy. Indeed, there are no online pharmacies registered with the DEA. How to Submit Comments to the DEA.

DEA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NORML: DEA Reports Significant Uptick in Marijuana-Related Seizures, Arrests

Cannabis Law Report

million cultivated marijuana plants and made more than 6,600 marijuana-related arrests in 2021, according to annual data compiled by the US Drug Enforcement Administration. . Federal agents and their local partners also reported seizing of $103 million in assets in 2021 as part of the program — more than double the amount seized in 2020.

DEA 52
article thumbnail

AIMS v. Garland: A Disappointment for Psilocybin Advocates, but Progressive Policy May Still be on the Horizon

Cannabis Law Report

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.

DEA 52
article thumbnail

Cannabis News 02/12/2021

Nature's Way Medicine

The DEA would be mandated to approve applications for manufacturers to produce marijuana-derived, FDA-approved drugs. The bill would also require Health and Human Services (HHS) to consider the health benefits and risks of cannabis and look into policies that are preventing research on marijuana grown in legal states. Other News.

article thumbnail

A Strategy for Rescheduling Psilocybin

Canna Law Blog

Despite overwhelming evidence that psilocybin is misclassified, this barrier restricts research, stifles competition and innovation, and inhibits access. But only if it is made affordable and accessible. That power is typically delegated to the DEA. Psilocybin’s federal status as a Schedule I controlled substance is to blame.

article thumbnail

Emerge Law Group (OR): PSILOCYBIN THERAPY FOR PATIENTS WITH ADVANCED ILLNESS IN OREGON

Cannabis Law Report

September 30, 2021. Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment. Access Pursuant to the Oregon Psilocybin Services Act. The shelter provided by this approach depends on the policy of the U.S. Kathryn Tucker.

Therapy 52